Advances in Treatments of Myeloma

Eruption styles are broadly divided into magmatic, phreatomagmatic, and phreatic eruptions. The intensity of explosive volcanism is expressed using the Volcanic Explosivity Index (VEI), which ranges from 0 for Hawaiian-type eruptions to 8 for super volcanic eruptions. Magmatic eruptions are driven primarily by gas release due to decompression. Low-viscosity magma with little dissolved gas produces relatively gentle effusive eruptions. High-viscosity magma with a high content of dissolved gas produces violent explosive eruptions. The range of observed eruption styles is expressed from historical examples. Hawaiian eruptions are typical of volcanoes that erupt mafic lava with a relatively low gas content. These are almost entirely effusive, producing local fire fountains and highly fluid lava flows but relatively little tephra. They are named after the Hawaiian volcanoes. Phreatomagmatic eruptions are characterized by the interaction of rising magma with groundwater. They are driven by the resulting rapid buildup of pressure in the superheated groundwater. Phreatic eruptions are characterized by superheating of groundwater that comes in contact with hot rock or magma. They are distinguished from phreatomagmatic eruptions because the erupted material is all country rock; no magma is erupted.

In the present book, ten typical literatures about volcano eruption published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on volcano eruption. We hope this book can demonstrate advances in volcano eruption as well as give references to the researchers, students and other related people.

Sample Chapter(s)
Preface (85 KB)
Components of the Book:
  • Chapter 1
    Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
  • Chapter 2
    Evolution of Diagnostic Workup and Treatment for Multiple Myeloma 2013-2019
  • Chapter 3
    Epidemiology, Genetics and Treatment of Multiple Myeloma and Precursor Diseases
  • Chapter 4
    Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Physician’s Choice of Therapy in the Flatiron Health Multiple Myeloma Cohort Registry for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
  • Chapter 5
    Immune Responses to COVID-19 Booster Vaccinations in Intensively Anti-CD38 Antibody Treated Patients with Ultra-high-risk Multiple Myeloma: Results from the Myeloma UK (MUK) nine OPTIMUM Trial
  • Chapter 6
    Association Between Race and Treatment Patterns and Survival Outcomes in Multiple Myeloma: A Connect MM Registry Analysis
  • Chapter 7
    Regional Differences in Treatment and Outcome for Myeloma Patients in Sweden: A Population Based Swedish Myeloma Register Study
  • Chapter 8
    Quality of Life during and Following Sequential Treatment of Previously Untreated Patients with Multiple Myeloma: Findings of the Medical Research Council Myeloma IX Randomised Study
  • Chapter 9
    Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
  • Chapter 10
    Akt Inhibition Synergizes with Polycomb Repressive Complex 2 Inhibition in the Treatment of Multiple Myeloma
Readership: Students, academics, teachers and other people attending or interested in Treatments of Myeloma
Icahn School of Medicine at Mount Sinai, New York, New York, USA

Cambridge, Massachusetts, USA

Kari Hemminki
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Richard Houlston
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK

Thomas Martin
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.